Technology Reply Optimizes Pusterla 1880’s Quotation Management with Oracle AI Capabilities, Reducing the Estimation Time by 90%
29.4.2025 10:00:00 CEST | Business Wire | Press Release
Technology Reply, the Reply Group company specialising in designing solutions based on Oracle technologies, today announced the development of an AI-based solution for managing the quotation process at Pusterla 1880. The implementation has reduced the time required to create new quotations to under five minutes and decreased the time needed to generate and validate cost estimates by 90%.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250429596543/en/
“Leveraging the AI capabilities offered by Oracle Cloud Infrastructure and Oracle Database 23ai, and supported by Technology Reply’s expertise, we have significantly streamlined our quotation process. This has enabled us to respond more quickly to customer requests while reducing the risk of errors in our decision-making,” said Luca Meana, President, Pusterla 1880.
Pusterla 1880, a company with over 140 years of experience in luxury packaging production, faced increasing complexity in its quoting processes due to product customization and cost variability. Pusterla 1880 sought to improve the efficiency and precision in responding to customer requests by adopting a solution that automates the entire process, moving beyond traditional manual methods.
The solution consists of a set of dedicated AI agents, developed and operated on Oracle Cloud Infrastructure (OCI) and Oracle Database solution is designed to generate accurate cost estimates and pricing proposals. Each agent in the system handles and automates a specific phase of the quoting process using data stored in Oracle Database 23ai and retrieval-augmented generation. The agents in the system include an AI Configurator Assistant that analyzes historical data to generate new product production processes, a Brief Analysis Assistant that automatically extracts technical specifications from customer briefs, and an Estimates Assistant that automates and optimizes decision-making by leveraging past data stored in Oracle Database 23ai. This agent generates dynamic queries based on model annotations within the structured data model, enhancing the accuracy and speed of the estimation process. Additionally, it uses Oracle AI Vector Search to retrieve relevant financial documents and train the LLM with contextual business knowledge, further improving the quality of responses.
“Leveraging the AI capabilities offered by Oracle Cloud Infrastructure and Oracle Database 23ai, and supported by Technology Reply’s expertise, we have significantly streamlined our quotation process. This has enabled us to respond more quickly to customer requests while reducing the risk of errors in our decision-making,” said Luca Meana, President, Pusterla 1880.
“Our collaboration with Technology Reply is revolutionizing AI-driven business processes by harnessing the power of Oracle Autonomous Database and AI Vector Search. Through the Pusterla 1880 project, we are demonstrating how AI can seamlessly integrate into enterprises, driving intelligent automation and operational efficiency. With Oracle Cloud Infrastructure as the foundation, we are enabling businesses to unlock new levels of innovation and performance,” said Tirthankar Lahiri, SVP, Mission-Critical Data and AI Engines.
By adopting the joint solution developed with Technology Reply and Oracle, Pusterla 1880 has achieved significant benefits, including increased quote accuracy, reduced response times, and more efficient resource management. The solution has also enhanced pricing accuracy, reducing the risk of misquoted estimates and improving the alignment of quotes with production costs. The system empowers data-driven decision-making in pricing strategies, leading to more strategic and consistent outcomes.
Pusterla 1880
Pusterla 1880 is a leading company in luxury packaging production with a long tradition and a strong commitment to sustainability and innovation. Through continuous research into innovative materials and original technical solutions, Pusterla offers high-quality, customised packaging with a focus on environmental sustainability.
www.pusterla1880.com
Technology Reply
Technology Reply [MTA, STAR: REY, ISIN: IT0005282865], part of the Reply Group, specialises in designing innovative solutions based on Oracle technologies. With over 25 years of experience, it supports companies in their innovation and digital transformation processes by integrating AI, Machine Learning, Big Data, and emerging technologies.
www.reply.com
Trademarks
Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250429596543/en/
Contacts
Press contact:
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594
Irene Caia
i.caia@reply.com
Tel. +39 02 535761
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom